Denervation of the REnal Artery in Metabolic Syndrome

Inclusion Criteria: * Patients should have a high fasting glucose (fasting serum glucose ≥5.6 mmol/L (≥100 mg/dL)), without the use of antidiabetic drugs at the time of inclusion AND should have a 24 hour ambulatory SBP \>130 mmHg, without the use of antihypertensive drugs at the time of inclusion. * Patients should fulfil one or more other criteria to meet the definition of the metabolic syndrome. * Individual understands the study procedures, alternative treatments available, risks involved with the study and voluntarily agrees to participate by giving informed consent. * Individual is over 18 years of age on the day of signing informed consent. Exclusion Criteria: * SBP \>180 mmHg and/or DBP \>110 mmHg during one or more screening measurements. * 24-hour ambulatory SBP \>170 mmHg and/or 24-hour ambulatory DBP \>100 mmHg at time of inclusion. * Individual is treated with more than one type of antihypertensive medication at time of inclusion. * Individual is treated with more than one type of drug for diabetes mellitus 2 at time of inclusion and/or the medication for DM type 2 can not be stopped. * Individual has a treatable secondary cause of hypertension. * Individual has renal artery anatomy that is ineligible for treatment. * Individual has an estimated glomerular filtration rate (eGFR) of \<45mL/min/1.73m2, using the MDRD calculation. * Individual has type 1 diabetes mellitus. * Individual has experienced a myocardial infarction, unstable angina pectoris, or a cerebrovascular accident within 6 months of the screening visit, or has widespread atherosclerosis, with documented intravascular thrombosis or unstable plaques. * Individual has scheduled or planned surgery or cardiovascular intervention in the next 6 months. * Individual has hemodynamically significant valvular heart disease for which reduction of BP would be considered hazardous. * Individual has an implantable cardioverter defibrillator (ICD) or pacemaker whose settings cannot allow for RF energy delivery. * Individual has any serious medical condition, which in the opinion of the investigator, may adversely affect the safety and/or effectiveness of the participant or the study (i.e., patients with clinically significant peripheral vascular disease, abdominal aortic aneurysm, bleeding disorders such as thrombocytopenia, haemophilia, or significant anaemia). * Individual is pregnant, nursing or planning to be pregnant. * Individual has a known, unresolved history of drug use or alcohol dependency, lacks the ability to comprehend or follow instructions, or would be unlikely or unable to comply with study follow-up requirements. * Individual is currently enrolled in another investigational drug or device trial. * Individual is currently being treated with any of the following medications: * Drugs that cause salt retention (e.g., systemic corticosteroids and fludrocortisone) * Acenocoumarol or phenprocoumon that cannot be temporarily stopped for the procedure.